LCTX - Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.
As of May 15, 2026: spot at $1.27, ATM IV 174.3%, net GEX $7.6K.
- Sector
- Healthcare
- Industry
- Biotechnology
- Market Cap
- $318.8M
- Beta
- 1.60
- 52-Week Range
- 0.45-2.09
- CEO
- Brian Culley
- Employees
- 70
- IPO Date
- Mar 5, 1992
- Exchange
- AMEX
What LCTX Looks Like to Options Traders Today
IV rank of 32.3% sits near the 1-year median, where strategy choice depends on directional conviction and the event calendar rather than vol regime alone; positive net gamma exposure ($7.6K) means dealers hedge against trend, damping realized volatility and biasing price toward heavy-OI strikes; the 25-delta skew (2.720) prices calls richer than puts, often reflecting upside speculation or squeeze risk.
What This Page Covers
The LCTX overview links into per-metric analysis views: max pain, gamma exposure, volatility skew, expected move, options chain, open interest history, and aggregate Greeks. Microstructure data is available on short interest, short volume, fail-to-deliver, and market structure. Corporate data is on fundamentals, earnings, analyst ratings, and insider trading.
Frequently asked LCTX overview questions
- What is LCTX?
- LCTX is the ticker symbol for Lineage Cell Therapeutics, Inc., a listed security. Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. Listed on AMEX. LCTX is the equity ticker shown on this page; equity options traders use the security for directional, volatility, and income strategies via the listed options chain.
- What does the LCTX options snapshot look like today?
- As of May 15, 2026, the LCTX options snapshot shows spot at $1.27, ATM IV 174.3%, IV rank 32.3%, net GEX $7.6K, expected move 49.97%. The full options chain, Greeks by strike and expiration, per-strike open-interest distribution, dealer gamma and delta exposure, and the volatility skew surface are linked from this overview page. Each per-metric route refreshes once per trading session and reflects the most recent close-of-business listed-options state.
- What are LCTX's key statistics?
- Lineage Cell Therapeutics, Inc. (LCTX) carries a market capitalization of $318.8M, beta of 1.60 relative to the broader market, 52-week range of 0.45-2.09. Full income statement, balance sheet, cash flow, and TTM ratio history is on the per-ticker fundamentals page; daily price history and 52-week levels are accessible from the same view. These structural inputs frame how the options market prices implied volatility around earnings windows and capital events.
- What sector or industry does LCTX belong to?
- Lineage Cell Therapeutics, Inc. operates in the Healthcare sector, in the Biotechnology industry. Sector classification affects how the ticker correlates with sector ETFs, how it reacts to macro factors like rate moves and commodity prices, and how its options pricing compares to sector peers. Compare LCTX's implied volatility and skew against sector benchmarks to gauge whether the options market is pricing single-name or systemic risk relative to the broader peer group.
- How current is the LCTX data on this page?
- The options snapshot above is dated May 15, 2026 and refreshes once per session, with all per-strike Greeks and exposure aggregates recomputed at the daily close. Company-profile fields (sector, industry, market cap, P/E, IPO date) refresh from the vendor feed nightly. Financials and earnings refresh as 10-K and 10-Q filings are parsed (typically within several business days of the actual report). FINRA microstructure data refreshes on the source's cadence (daily for short volume, bi-monthly for short interest, weekly for the OTC volume file, twice-monthly for SEC FTD).